Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy F Cobbold

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Medrxiv : the Preprint Server for Health Sciences|December 11, 2023
Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsJun Liu, Sile Hu, Lingyan Chen, et al.
The Lancet. Gastroenterology & Hepatology|February 7, 2020
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation studyPhilip N Newsome, Magali Sasso, Jonathan J Deeks, et al.
The Lancet. Gastroenterology & Hepatology|May 1, 2022
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest GroupStuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, et al.
The Lancet. Gastroenterology & Hepatology|January 18, 2021
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysisDavid Petroff, Valentin Blank, Philip N Newsome, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
The Lancet. Gastroenterology & Hepatology|May 3, 2026
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensusJeremy F Cobbold, Hamish Miller, Kate Hallsworth, et al.
Gut|May 18, 2021
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysisFerenc Emil Mózes, Jenny A Lee, Emmanuel Anandraj Selvaraj, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Medrxiv : the Preprint Server for Health Sciences|December 11, 2023
Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsJun Liu, Sile Hu, Lingyan Chen, et al.
The Lancet. Gastroenterology & Hepatology|February 7, 2020
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation studyPhilip N Newsome, Magali Sasso, Jonathan J Deeks, et al.
The Lancet. Gastroenterology & Hepatology|May 1, 2022
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest GroupStuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, et al.
The Lancet. Gastroenterology & Hepatology|January 18, 2021
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysisDavid Petroff, Valentin Blank, Philip N Newsome, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
The Lancet. Gastroenterology & Hepatology|May 3, 2026
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensusJeremy F Cobbold, Hamish Miller, Kate Hallsworth, et al.
Gut|May 18, 2021
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysisFerenc Emil Mózes, Jenny A Lee, Emmanuel Anandraj Selvaraj, et al.
Pageof 4